Loading clinical trials...
Loading clinical trials...
Relative Bioavailability of 40 mg/0.4 mL of BI 695501 Compared to 40 mg/0.8 mL of BI 695501 Formulation Following Single Subcutaneous Administration in Healthy Male and Female Subjects (a Double Blind, Randomised, Single-dose, Parallel-arm Study)
Conditions
Interventions
BI 695501 - higher concentration
BI 695501 - lower concentration
Locations
2
United States
Miami Research Associates, Inc
Miami, Florida, United States
QPS MO
Springfield, Missouri, United States
Start Date
February 18, 2022
Primary Completion Date
August 29, 2022
Completion Date
August 29, 2022
Last Updated
March 15, 2024
NCT00104325
NCT07470866
NCT07388667
NCT07221448
NCT06637865
NCT07118891
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions